The Column Group

The Column Group (TCG) is a science-driven venture capital firm that makes significant financial and operational commitments to build early-stage drug discovery companies based on their unique scientific platforms and potential to deliver multiple breakthrough therapeutics. TCG's investment strategy runs counter to the prevailing trend in life sciences venture capital toward assembling diversified portfolios of later-stage, single product-oriented companies. Instead, TCG takes the long view in making investments, recognizing that significant time is often required to generate significant value. The firm assembles a focused portfolio of 'big idea' companies, each built from the ground up with platforms capable of generating multiple differentiated product opportunities. TCG deploys an edge-to-edge investment model, supporting companies from inception through exit through an ecosystem of funds including Platform funds, Opportunity funds, TCG Labs-Soleil, and TCG Crossover (TCGX).